This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits CI
Meridian Bioscience, Inc. announced that it has received KRW 128.772575398 billion in funding CI
Meridian Bioscience, Inc. announced that it expects to receive KRW 128.772575393 billion in funding CI
Meridian Bioscience, Inc. announced that it has received KRW 258.225164381 billion in funding from Columbus Holding Company CI
Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex CI
Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding CI
Meridian Bioscience, Inc. Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay CI
Meridian Bioscience, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
SD Biosensor, SJL Partners Acquire Meridian Bioscience MT
Meridian Bioscience, Inc.(NasdaqGM:VIVO) dropped from NASDAQ Composite Index CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Healthcare Equipment Select Industry Index CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 600 CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Composite 1500 CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Global BMI Index CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P TMI Index CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 1000 CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 600 Health Care CI
SD BioSensor, Inc and SJL Partners completed the acquisition of Meridian Bioscience, Inc. from Impactive Capital LP, BlackRock, Inc., The Vanguard Group, Inc, Royce & Associates, LP and others. CI
DoubleVerify Holdings to Replace Meridian Bioscience in S&P SmallCap 600 MT
Meridian Bioscience Says Closing Date of Pending Merger With SD Biosensor, Others Pushed Back to Jan. 31 MT
Meridian Bioscience Fiscal Q4 Adjusted EPS, Revenue Decline MT
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q4 Revenue $65.7M MT
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q4 EPS $0.20 MT
Meridian Bioscience, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Meridian Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2022 CI
Chart Meridian Bioscience, Inc.
More charts
Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized polymerase chain reaction (PCR) master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi'in, Israel. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany.
More about the company
  1. Stock Market
  2. Equities
  3. VIVO Stock
  4. News Meridian Bioscience, Inc.
  5. Meridian Bioscience Posts Decline in Fiscal Q3 Adjusted Net Earnings, Higher Revenue, Scraps 2022 Guidance